Effects of strontium ranelate on spinal osteoarthritis progression

O Bruyere, D Delferriere, C Roux, J D Wark, T Spector, J-P Devogelaer, Kim Brixen, S Adami, J Fechtenbaum, S Kolta, J-Y Reginster

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Udgivelsesdato: 2008-Mar
OriginalsprogEngelsk
TidsskriftAnnals of the Rheumatic Diseases
Vol/bind67
Udgave nummer3
Sider (fra-til)335-339
Antal sider4
ISSN0003-4967
DOI
StatusUdgivet - 1. mar. 2008

Fingeraftryk

strontium ranelate
Spine Osteoarthritis
Health
Placebos
Quality of Life
Sclerosis
X rays
X-Rays

Citer dette

Bruyere, O., Delferriere, D., Roux, C., Wark, J. D., Spector, T., Devogelaer, J-P., ... Reginster, J-Y. (2008). Effects of strontium ranelate on spinal osteoarthritis progression. Annals of the Rheumatic Diseases, 67(3), 335-339. https://doi.org/10.1136/ard.2007.075572
Bruyere, O ; Delferriere, D ; Roux, C ; Wark, J D ; Spector, T ; Devogelaer, J-P ; Brixen, Kim ; Adami, S ; Fechtenbaum, J ; Kolta, S ; Reginster, J-Y. / Effects of strontium ranelate on spinal osteoarthritis progression. I: Annals of the Rheumatic Diseases. 2008 ; Bind 67, Nr. 3. s. 335-339.
@article{ed830e305c2411ddb1a1000ea68e967b,
title = "Effects of strontium ranelate on spinal osteoarthritis progression",
abstract = "OBJECTIVE: The aim of this study was to determine whether a 3-year treatment with strontium ranelate could delay the progression of spinal osteoarthritis (OA). METHODS: This study was a post-hoc analysis of pooled data from the Spinal Osteoporosis Therapeutic Intervention (SOTI) and TReatment Of Peripheral OSteoporosis (TROPOS) trials performed on 1105 women with osteoporosis and concomitant radiological spinal OA at baseline, and for whom lumbar x-rays were available at baseline and over the 3-year treatment period. The presence and severity of osteophytes, disc space narrowing and sclerosis in the lumbar intervertebral spaces was graded according to a validated method, and an overall OA score was calculated for each intervertebral space. Back pain (measured on a five-point Likert scale only in SOTI) and health-related quality of life (SF-36 questionnaire) were assessed at baseline and after 3 years. Patients who suffered an incident or progressive vertebral fracture during the study were excluded from the analysis. RESULTS: The proportion of patients with worsening overall spinal OA score was reduced by 42{\%} in the strontium ranelate group, compared with placebo (RR, 0.58; 95{\%} CI, 0.42 to 0.79; p = 0.0005). Significantly more patients in the strontium ranelate group experienced an improvement in back pain after 3 years, compared with placebo (p = 0.03), while no significant difference was observed in terms of health-related quality of life between these patient groups. CONCLUSIONS: The results of this post-hoc analysis suggest that strontium ranelate could reduce the progression of the radiographic features of spinal OA and back pain in women with osteoporosis and prevalent spinal OA.",
keywords = "Aged, Back Pain, Bone Density Conservation Agents, Disease Progression, Double-Blind Method, Female, Follow-Up Studies, Humans, Middle Aged, Organometallic Compounds, Osteoarthritis, Osteoporosis, Postmenopausal, Severity of Illness Index, Spinal Diseases, Thiophenes, Treatment Outcome",
author = "O Bruyere and D Delferriere and C Roux and Wark, {J D} and T Spector and J-P Devogelaer and Kim Brixen and S Adami and J Fechtenbaum and S Kolta and J-Y Reginster",
year = "2008",
month = "3",
day = "1",
doi = "10.1136/ard.2007.075572",
language = "English",
volume = "67",
pages = "335--339",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "B M J Group",
number = "3",

}

Bruyere, O, Delferriere, D, Roux, C, Wark, JD, Spector, T, Devogelaer, J-P, Brixen, K, Adami, S, Fechtenbaum, J, Kolta, S & Reginster, J-Y 2008, 'Effects of strontium ranelate on spinal osteoarthritis progression', Annals of the Rheumatic Diseases, bind 67, nr. 3, s. 335-339. https://doi.org/10.1136/ard.2007.075572

Effects of strontium ranelate on spinal osteoarthritis progression. / Bruyere, O; Delferriere, D; Roux, C; Wark, J D; Spector, T; Devogelaer, J-P; Brixen, Kim; Adami, S; Fechtenbaum, J; Kolta, S; Reginster, J-Y.

I: Annals of the Rheumatic Diseases, Bind 67, Nr. 3, 01.03.2008, s. 335-339.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Effects of strontium ranelate on spinal osteoarthritis progression

AU - Bruyere, O

AU - Delferriere, D

AU - Roux, C

AU - Wark, J D

AU - Spector, T

AU - Devogelaer, J-P

AU - Brixen, Kim

AU - Adami, S

AU - Fechtenbaum, J

AU - Kolta, S

AU - Reginster, J-Y

PY - 2008/3/1

Y1 - 2008/3/1

N2 - OBJECTIVE: The aim of this study was to determine whether a 3-year treatment with strontium ranelate could delay the progression of spinal osteoarthritis (OA). METHODS: This study was a post-hoc analysis of pooled data from the Spinal Osteoporosis Therapeutic Intervention (SOTI) and TReatment Of Peripheral OSteoporosis (TROPOS) trials performed on 1105 women with osteoporosis and concomitant radiological spinal OA at baseline, and for whom lumbar x-rays were available at baseline and over the 3-year treatment period. The presence and severity of osteophytes, disc space narrowing and sclerosis in the lumbar intervertebral spaces was graded according to a validated method, and an overall OA score was calculated for each intervertebral space. Back pain (measured on a five-point Likert scale only in SOTI) and health-related quality of life (SF-36 questionnaire) were assessed at baseline and after 3 years. Patients who suffered an incident or progressive vertebral fracture during the study were excluded from the analysis. RESULTS: The proportion of patients with worsening overall spinal OA score was reduced by 42% in the strontium ranelate group, compared with placebo (RR, 0.58; 95% CI, 0.42 to 0.79; p = 0.0005). Significantly more patients in the strontium ranelate group experienced an improvement in back pain after 3 years, compared with placebo (p = 0.03), while no significant difference was observed in terms of health-related quality of life between these patient groups. CONCLUSIONS: The results of this post-hoc analysis suggest that strontium ranelate could reduce the progression of the radiographic features of spinal OA and back pain in women with osteoporosis and prevalent spinal OA.

AB - OBJECTIVE: The aim of this study was to determine whether a 3-year treatment with strontium ranelate could delay the progression of spinal osteoarthritis (OA). METHODS: This study was a post-hoc analysis of pooled data from the Spinal Osteoporosis Therapeutic Intervention (SOTI) and TReatment Of Peripheral OSteoporosis (TROPOS) trials performed on 1105 women with osteoporosis and concomitant radiological spinal OA at baseline, and for whom lumbar x-rays were available at baseline and over the 3-year treatment period. The presence and severity of osteophytes, disc space narrowing and sclerosis in the lumbar intervertebral spaces was graded according to a validated method, and an overall OA score was calculated for each intervertebral space. Back pain (measured on a five-point Likert scale only in SOTI) and health-related quality of life (SF-36 questionnaire) were assessed at baseline and after 3 years. Patients who suffered an incident or progressive vertebral fracture during the study were excluded from the analysis. RESULTS: The proportion of patients with worsening overall spinal OA score was reduced by 42% in the strontium ranelate group, compared with placebo (RR, 0.58; 95% CI, 0.42 to 0.79; p = 0.0005). Significantly more patients in the strontium ranelate group experienced an improvement in back pain after 3 years, compared with placebo (p = 0.03), while no significant difference was observed in terms of health-related quality of life between these patient groups. CONCLUSIONS: The results of this post-hoc analysis suggest that strontium ranelate could reduce the progression of the radiographic features of spinal OA and back pain in women with osteoporosis and prevalent spinal OA.

KW - Aged

KW - Back Pain

KW - Bone Density Conservation Agents

KW - Disease Progression

KW - Double-Blind Method

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Middle Aged

KW - Organometallic Compounds

KW - Osteoarthritis

KW - Osteoporosis, Postmenopausal

KW - Severity of Illness Index

KW - Spinal Diseases

KW - Thiophenes

KW - Treatment Outcome

U2 - 10.1136/ard.2007.075572

DO - 10.1136/ard.2007.075572

M3 - Journal article

VL - 67

SP - 335

EP - 339

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 3

ER -

Bruyere O, Delferriere D, Roux C, Wark JD, Spector T, Devogelaer J-P et al. Effects of strontium ranelate on spinal osteoarthritis progression. Annals of the Rheumatic Diseases. 2008 mar 1;67(3):335-339. https://doi.org/10.1136/ard.2007.075572